This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as January 1, 2023 (the “Effective Date”), and is entered into by Acesis Biomed US, Inc., with a business address at 9233 Park Meadows Drive Suite 108, Lone Tree, Colorado 80124, USA (the “Company”), and Dr. Ravi Kacker with a business address at 67 Union St #308, Natick, Massachusetts 01760 (the “Advisor”). This Agreement shall replace and supersede any and all previous written agreements between the Company and Advisor regarding Scientific Advisory Board Services.
Scientific Advisory Board Agreement • January 10th, 2008 • Rxi Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
Contract Type January 10th, 2008 JurisdictionThis Scientific Advisory Board Agreement (the “Agreement”) dated as of February 26, 2007, is made by Michael P. Czech, Ph.D. (the “SAB Member”) and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi” and together with the SAB Member, the “Parties”). The SAB Member is a faculty member at the University of Massachusetts.
Scientific Advisory Board Agreement • November 5th, 2010 • Medgenics, Inc. • New York Contract Type November 5th, 2010 JurisdictionTHIS AGREEMENT (the “Agreement”) dated as of 22 October 2008 (“Effective Date”) is made by and between Medgenics, Inc. located at 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182, USA (the “Company”); and
Scientific Advisory Board Agreement • March 7th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
Contract Type March 7th, 2018 JurisdictionThis Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of March 1, 2018 (the “Effective Date”), and is entered into by IASO BioMed Inc., with a business address at 7315 East Peakview Ave., Centennial, CO 80111, USA (the “Company”), and Dr. Costas Karatzas personally or through CNKonsulting with a business address at _____________________________ (the “Advisor”).
Scientific Advisory Board Agreement • August 8th, 2022 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type August 8th, 2022 JurisdictionThis SCIENTIFIC ADVISORY BOARD Agreement (this “Agreement”) is entered into as of June 1, 2022 (the “Effective Date”) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (“Stoke”) and Adrian Krainer, Ph.D. (“Advisor”). Advisor has unique skills and knowledge pertinent to Stoke’s business and Stoke desires to retain Advisor as a member of Stoke’s Scientific Advisory Board (“SAB”) under the terms of this Agreement.
Scientific Advisory Board Agreement • June 10th, 2015 • E-Qure Corp. • Wholesale-misc durable goods • California
Contract Type June 10th, 2015 JurisdictionTHIS ADVISORY BOARD AGREEMENT is made effective as of January 1, 2015, (the "Effective Date") by and between E-QURE Corp, a (the "Company"), and Dr. Ben Zion Weiner (the "Advisor").
Scientific Advisory Board Agreement • July 11th, 2011 • Stem Cell Assurance, Inc. • Services-misc health & allied services, nec • Florida
Contract Type July 11th, 2011 JurisdictionSCIENTIFIC ADVISORY BOARD AGREEMENT, dated as of June 10, 2011, by and between NAIYER IMAM, M.D. (the “Advisor”), having an address at 6185 Steeplechase Drive, Roanoke, Virginia, and STEM CELL ASSURANCE, INC., a Nevada corporation (the “Company”), having offices at 555 Heritage Drive, Suite 130, Jupiter, Florida 33458.
Scientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • California
Contract Type July 1st, 2021 JurisdictionThis Scientific Advisory Board Agreement (“Agreement”), effective as of June 18, 2012 (“Effective Date”), is made between Caribou Biosciences, Inc. (“Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”) (each may be referred to below individually as a “party” and collectively as the “parties”).
Scientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
Contract Type July 1st, 2021This Amendment No. 5 to Scientific Advisory Board Agreement (“Amendment No. 5”), effective January 1, 2020 (“Amendment No. 5 Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016, Amendment No. 3 to Scientific Advisory Board Agreement, dated January 1, 2017, and Amendment No. 4 to Scientific Advisory Board Agreement, dated March 31, 2018 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used in this Amendment No. 5 that is not defined herein has the meaning ascribed to it in the Agreement.
Scientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
Contract Type July 1st, 2021This Amendment No. 3, effective January 1, 2017 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated June 18, 2012, and Amendment No. 2 to Scientific Advisory Board Agreement, dated May 31, 2016 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined has the meaning ascribed to it in the SAB Agreement.
Scientific Advisory Board Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)
Contract Type July 1st, 2021This Amendment No. 2, effective May 31, 2016 (“Amendment Effective Date”), is made to the Scientific Advisory Board Agreement, dated June 18, 2012, as amended by Amendment No. 1 to Scientific Advisory Board Agreement, dated April 12, 2014 (collectively, the “SAB Agreement”), and is by and between Caribou Biosciences, Inc. (the “Company”), a Delaware corporation having its address at 2929 7th Street, Suite 105, Berkeley, CA 94710, and Jennifer A. Doudna (“Advisor”), an individual. Each may be referred to as a “party” and collectively as the “parties.” Any capitalized term used herein that is not defined shall have the meaning ascribed to it in the SAB Agreement.
Scientific Advisory Board Agreement • September 20th, 2001 • Endocare Inc • Electromedical & electrotherapeutic apparatus • California